Antibiotics

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• Penicillin
• Cephalosporins
• Macrolides
• Quinolones
• Carbapenems
• Other Antibiotics
• Aminoglycosides
• Tetracyclines
• Sulfonamides
• Mupirocin
• Glycopeptides
• Synercid
• Oxazolidinones
• Linezolid

II. EXECUTIVE SUMMARY

1. Industry Overview

• Antibiotic Resistance and Generic Competition to Impact Long Term Growth
• Current & Future Analysis

2. Market Dynamics

• Anti-Bacterials Segment Drives Global Anti-Infectives Market
• Antibiotic Resistance - A Primary Growth Inhibitor
• Antibiotic-Resistant Bacteria by Type
• Patent Expiries Commoditize Antibiotics
• Patent Expiries of Leading Drugs in the Recent Past, Current, and Future
• Anti-MRSA Antibiotics Find Their Way..
• Table 1: Estimated Revenues Generated by Leading MRSA Antibiotic Drugs in 2005 (includes corresponding Graph/Chart)
• Key Antibiotics in Pipeline

3. Competition

• Highly Competitive Market
• Table 2: Leading Players in the Worldwide Antibiotics Market (2006): Percentage Breakdown by Value Sales for Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart)
• GlaxoSmithKline - The Undisputed Leader of Penicillin Market
• Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding Graph/Chart)
• GlaxoSmithKline Leads Cephalosporin Market
• Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart)
• Pfizer Dominates Macrolides Market
• Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart)
• Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic
• Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart)
• Merck Rules Carbapenems Market
• Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart)

4. Product Overview

• Antibiotics - An Introduction
• Antibiotic Resistance
• ? -Lactams
• Classification of Antibiotics
• Sulfonamides
• Treatment
• Effects of the Drug
• Mupirocin
• Glycopeptides
• Synercid
• Oxazolidinones
• Linezolid

5. Research Findings

• Cephalosporins Effective when Compared to Penicillin
• FDA Bans Baytril Antibiotic for Chickens
• Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death
• Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug Resistance

6. FDA Approvals/Patents

• MiddleBrook Obtains NDA Approval for MOXATAG™
• J&JPRD Seeks FDA Approval for Doripenem Antibiotic
• J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole
• GSK Receives Approval for ALTARGO® in Europe
• APL Receives FDA Approval for Cefpodoxime Proxetil
• Cubist Receives Approval to Market CUBICIN in Canada
• Cubist Obtains Approval to Market CUBICIN for Added Indications in EU
• Cubist Gains Approval for CUBICIN in Taiwan and South Korea
• Cethromycin Achieves FDA' s Orphan Drug Designation
• FDA Approves Wockhardt' s Cefotaxime Injection
• FDA Approves Doxycycline Tablets
• FDA Approves Clarithromycin
• FDA Approves Doxycycline Tablets For The US Market
• Johnson & Johnson Applies Doripenem For FDA Approval
• FDA Certifies Antibioticos do Brasil' s Plant
• FDA Certifies ANDA For Cefdinir Capsules
• US FDA Approves Teva' s Cefprozil Tablets
• FDA Certifies ANDA for Cephalexin Capsules
• American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection, USP
• Advancis' s Keflex Receives FDA Approval
• Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US
• Wyeth' s Mylotarq Receives Government' s Approval
• FDA Approves Generic Version of Zithromax
• Pfizer Wins FDA Approval for Zmax™
• Venus Remedies Files Second PCT for New Cephalosporins
• Falcon Gains US FDA Approval for its Generic Anti-Infective Solution
• Cadilla Receives FDA Approval to Market Clindamycin

7. Recent Industry Activity

• 3i to Buy Alpharma Unit
• NCPC to Acquire Stake in DSM' s Antibiotics Division
• ULL Establishes New Antibiotics Unit in Himachal Pradesh
• Biocat to Expand Presence in the Indian Market
• PRWT Acquires Cherokee Chemical Unit from Merck
• CSPC Joins Hands with Indonesian Firms
• Nisshin-Kyorin to Merge with Kyorin Pharmaceutical
• Schering-Plough Acquires Organon BioSciences
• GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals
• Iroko Bags Canadian Rights to Vancocin®
• Cubist Licenses CUBICIN Rights to Merck
• Sagent Partners with Astral to Develop Injectable Antibiotics
• MR Healthcare to Manufacture New Antibiotics & Medicines
• Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo
• C&O Pharmaceutical to Distribute Meiact in China
• Bioton Signs Deal to Market Antibiotics in Russia
• Toyama Gains Marketing Approval for Geninax® in Japan
• Forest Laboratories Acquires Cerexa
• Oscient Modifies Licensing Agreement With LG Life Sciences
• Orchid Sign Licensing & Distribution Pact With Actavis
• Forest Laboratories Revokes Partnership With Replidyne
• SRI and Blanca Collaborate To Develop & Test Carbacephem
• AstraZeneca To Expand Research Center For Antibiotics
• Jade Pharmaceutical Begins Levofloxacin' s Production in China
• Reyoung To Start Antibiotic Production At New Facility
• Toyama Begins T-705 Clinical Trials
• SmPC For Sanofi-Aventis' Ketek® Updated
• Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France
• Antibiotice Plans To Infuse Funds For Antibiotics Production
• UAE Approves Pfizer' s Zithromax SD
• Premier Takes Over Cereplex
• Laboratorios Roemmers Acquires Argentine Pharmaceutical' s Business
• Ranbaxy Adds Be-Tabs
• AstraZeneca Purchases Vancocin® From Eli Lilly
• Ranbaxy Laboratories Limited Acquires Ethimed NV
• Ranbaxy Laboratories Limited Acquires Terapia SA
• Ranbaxy Italia Acquires Allen Generic Business of GlaxoSmithKline
• Connetics Acquires Sales Organization of PediaMed
• Wyeth Increases Stake in Wyeth KK to 80%
• Sankyo Pharma, Daiichi Medical Research and Daiichi Pharmaceutical Merge
• Merck & Co. and Paratek Sign Development & License Pact
• Wakunga and Rib-X Sign Licensing Pact
• Pfizer Settles Infringement Lawsuit With Teva
• Astellas Extends Agreement With Theravance
• Astellas and Theravance Sign Collaboration Agreement
• Cubist and AstraZeneca Sign License Pact
• Astellas Pharma and Sanofi-Aventis Revoke Marketing Pact
• Achaogen Bags Licensing Agreement from Isis
• Pfizer Bags Rights from Oscient to Market Antibiotic in Mexico
• Replidyne Enters into Licensing Agreement with Forest Laboratories
• Toyama Chemical Co Ltd Enters into Licensing Agreement with Astellas Pharma
• AVAS' Majority Stake To Be Sold
• NIH Grants US$3 Million To PolyMedix For Antibiotics
• Wyeth' s Tygacil Achieves European Approval
• Chiron' s Cubicin® Receives Marketing Grant In The EU
• Vietnam Bans Antibiotics In Aquaculture
• Sance Pharmaceuticals Establishes Sance Laboratories
• Caps Holdings Plans to Re-enter Penicillin Market
• Alkem Establishes Sterile Cephalosporin Unit
• Novartis Completes Chiron Acquisition
• Toyama Submits New Drug Application For Quinolone Antibiotic Compound
• China Pharma Receives GMP Certification For Cephalosporin Antibiotic Production
• Venus Remedies Files For FDC Approval
• Sankyo Acquires rival Daiichi Pharmaceutical for US$ 7 Billion
• Daiichi Pharmaceutical Takes Over Daiichi Suntory Pharma
• Pfizer Acquires Idun Pharmaceuticals
• Pfizer Acquires Vicuron Pharmaceuticals
• Pfizer Acquires Bioren
• Novartis Acquires Eon Labs
• Kyorin Pharmaceutical Acquires Stake in Toyo Pharmar
• Targanta Acquires InterMune' s Late-Stage Antibiotic
• Novartis Acquires Hexal
• TB Alliance and Bayer Partner in Clinical Trials
• SBC Communications Enters into Agreement with Pfizer for Managed Voice Services
• Vicuron Extends Oral Antibiotics Development Agreement With Pfizer
• Orchid Chemicals Signs Distribution Agreement with Mayne Pharma
• Cubist Pharmaceuticals Inks Agreement with ACS Dobfar
• Orchid Chemicals Inks Marketing Agreement with Alpharma
• Lupin and DSM Anti-Infectives Sign Agreement to Market Cephalosporins
• Ranbaxy to Market P&G' s Generic Drug
• Nectar Expands Capacity
• Novartis Establishes Novartis Holding Japan
• Sun Pharma Acquires Phlox Pharma
• Kyorin Takes Over ActivX
• Advancis Acquires Lilly' s Keflex Brand
• Enanta Enters into Partnership with Shionogi & Co.
• Toyama Signs Collaborative Agreement with Glaxo to Develop Antibacterial Agents
• Enanta and Shionogi Ink an Agreement to Market EP- 013420
• Orchid Inks Agreement with Apotex to Market Generic Antibiotics
• Toyama Signs Licensing Agreement for TN-3262a with Dong-A
• Toyama Inks License Agreement with Schering for T-3811
• Shionogi Wins Rights to Market Cedax in the US
• Connetics Enters Acne Market

8. Product Innovations/Introductions

• MIT Scientists Develop a New Antibiotic, Rhodostreptomycin
• Watson Pharma Introduces Biaxin XL' s Generic Version
• Toyama Launches New Garenoxacin Quinolone Antibiotic
• Wockhardt to Introduce Cefprozil in the US
• MSD India Launches Invanza in India
• Orchid Chemicals to Introduce Three New Drugs in the US
• DUSA Pharmaceuticals Releases ClindaReach™
• Mylan Releases Cipro' s Generic Version
• Macrolide Antibiotic Developed In the US
• University of Michigan Devises NMR Spectroscopy For Antibiotics
• Glycopeptide-Cephalosporin Antibiotics Developed In The US
• Neosil Tests NEO 101 Antibiotic
• New Antibiotic Developed By Canadian Inventors
• Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada
• Pencillin Binding Protein Found In Japan
• Venus Remedies Releases Mucomelt-Forte
• Baxter Launches Injectable Antibiotic, Zithromax
• Advancis Releases Keflex (750mg) Capsules
• Researchers Develop Antibiotic For MRSA
• Wyeth Releases Tygacil In The UK
• Nihon Pharmaceutical Releases Clarithomycin Antibiotic
• Daiichi Sankyo Engages In Quinolone Antibiotic Development
• Shionogi Commercializes Finibax
• Sandoz and Nomura Phase4 Ventures Launch Nabriva Therapeutics Forschungs GmbH
• Lilly' s Investigational Cancer Agent Reaches Phase III Clinical Trial
• Idemitsu Technofine Launches Antibacterial Product
• Galleon Develops Oral Aminoglycoside Antibiotic
• Advancis Introduces Keflex® Powder in the US
• Skin Test for Penicillin Comes Back into the Market
• Cubist Introduces New Registry Program
• Idemitsu Technofine Launches Antibacterial Product

9. Focus on Select Global Players

• Abbott Laboratories (USA)
• MiddleBrook™ Pharmaceuticals, Inc. (USA)
• Bayer HealthCare AG (Germany)
• Bristol-Myers Squibb Co. (USA)
• Cubist Pharmaceuticals, Inc. (USA)
• Daiichi Sankyo Company, Limited (Japan)
• Eli Lilly and Co. (USA)
• GlaxoSmithKline Plc (UK)
• Johnson & Johnson (USA)
• Kyorin Pharmaceutical Co., Ltd. (Japan)
• LG Life Sciences Limited (Korea)
• MiddleBrook™ Pharmaceuticals, Inc. (USA)
• Novartis AG (Switzerland)
• Pfizer Inc. (USA)
• Pliva d.d. (Croatia)
• Roche (Switzerland)
• Sanofi-Aventis SA (France)
• Takeda Pharmaceutical Company, Ltd. (Japan)
• Toyama Chemical Co., Ltd. (Japan)
• Wyeth Pharmaceuticals, Inc. (USA)

10. Global Market Perspective

• Table 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 9: World Long-term Projections for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 15: World Long-term Projections for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-term Projections for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 21: World Long-term Projections for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 22: World 10-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 23: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 24: World Long-term Projections for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 25: World 10-Year Perspective for Carbapenems by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 26: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 27: World Long-term Projectionsfor Other Antibiotics by Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 28: World 10-Year Perspective for Other Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Current and Future Analysis
  • Antibiotics Approved Between 2000 and 2005 in the United States
  • Competition
  • Table 29: Leading Players in the US Antibiotics Market (2006): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart)
  • Strategic Corporate Developments
  • Product Introductions/Innovations
  • FDA Approvals / Patents
  • Focus on Select Players
• B. Market Analytics
  • Table 30: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 31: US Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 32: US 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• Market Analysis
• Current And Future Analysis
• Strategic Corporate Developments
• Product Introductions/Innovations
• Table 33: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 34: Canadian Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 35: Canadian 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Current and Future Analysis
  • Strategic Corporate Developments
  • Product Introductions/Innovations
  • Focus on Select Players
• B. Market Analytics
  • Table 36: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 37: Japanese Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 38: Japanese 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Current and Future Analysis
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 39: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 40: European Long-term Projections for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 41: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 42: European Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 43: European 10-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 44: European 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • Current and Future Analysis
  • Trends
  • Over Consumption of Antibiotics - Cause of Concern
  • Strategic Corporate Developments
  • Sanofi-Aventis SA - A Key Player
• B. Market Analytics
  • Table 45: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 46: French Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 47: French 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

• A. Market Analysis
  • Current and Future Analysis
  • Strategic Corporate Developments
  • Bayer HealthCare AG - A Key Player
• B. Market Analytics
  • Table 48: German Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 49: German Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 50: German 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. Italy

• A. Market Analysis
  • Current and Future Analysis
  • Corporate Development
• B. Market Analytics
  • Table 51: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 52: Italian Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 53: Italian 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. The United Kingdom

• Market Analysis
• Current And Future Analysis
• Product Introduction
• GlaxoSmithKline Plc - A Key Player
• Table 54: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 55: UK Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 56: UK 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

• Market Analysis
• Table 57: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 58: Spanish Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 59: Spanish 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Rest of Europe

• A. Market Analysis
  • Current and Future Analysis
  • Strategic Corporate Developments
  • Product Launch
  • Focus on Select Players
• B. Market Analytics
  • Table 60: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 61: Rest of Europe Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 62: Rest of Europe 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

• A. Market Analysis
  • Current and Future Analysis
  • India
  • Rising Prices of Penicillin G to Affect Antibiotics Production
  • Strategic Corporate Developments
  • Product Introduction
  • FDA Approvals / Patents
  • Focus on Select Players
• B. Market Analytics
  • Table 63: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 64: Asia-Pacific Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 65: Asia-Pacific 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

6. Rest of World

• A. Market Analysis
  • Current and Future Analysis
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 66: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 67: Rest of World Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 68: Rest of World 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE